{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:40:33Z","timestamp":1789645233239,"version":"4.0.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejca.2017.03.018","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T07:15:48Z","timestamp":1492586148000},"page":"103-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Demyelinating polyradiculoneuropathy under combined BRAF\/MEK inhibitors"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-1723","authenticated-orcid":false,"given":"Perrine","family":"Devic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Amini-Adle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Camdessanch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.03.018_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1158\/2326-6066.CIR-13-0092","article-title":"Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy","volume":"1","author":"Johnson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2017.03.018_bib2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"De Maleissye","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.03.018_bib3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain\u2013Barr\u00e9 syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.03.018_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11060-004-1871-3","article-title":"Chronic inflammatory polyneuropathy revealing malignant melanoma","volume":"71","author":"Rousseau","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2017.03.018_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjd.12268","article-title":"Sarcoidosis associated with vemurafenib","volume":"169","author":"Adam","year":"2013","journal-title":"Br J Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917308365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917308365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T11:55:09Z","timestamp":1535889309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917308365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":5,"alternative-id":["S0959804917308365"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.03.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demyelinating polyradiculoneuropathy under combined BRAF\/MEK inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}